PRETIUM FRAMEWORKS LIMITED
Company number 09529286 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Based on the financial data for Pretium Frameworks Limited, here is a comprehensive financial health assessment.
Financial Health Score: B- (Good, with cautionary notes)
Explanation: The company demonstrates strong short-term financial health, with excellent liquidity and a rapid return to profitability from a previously distressed state. However, the score is tempered by significant reliance on director loans, a concentrated debtor book, and a rapid increase in liabilities that requires monitoring to ensure it does not outpace growth in revenue or cash collection.
1. Key Vital Signs
Cash Flow & Liquidity (The "Pulse"): - Cash at Bank: £159,666 (up from £54,459). This is a strong, healthy pulse. The company has significantly increased its readily available cash. - Net Current Assets (Working Capital): £389,850 (up from £244,521). This is a very healthy level of working capital, indicating the company can easily meet its short-term obligations (due within one year). The "current ratio" (Current Assets / Current Liabilities) is a robust 1.49, meaning for every £1 of short-term debt, the company has £1.49 in liquid assets.
Profitability & Reserves (The "Constitution"): - Shareholders' Funds (Net Worth): £388,211 (up from £234,902). This represents a significant increase in the company's underlying value, a clear sign of a strong constitution. This is a remarkable turnaround from a negative net worth of -£213,967 in 2019. - Profit and Loss Reserve: £388,111. This confirms that the company has generated substantial retained profits over the past few years, moving from a state of distress to significant financial strength.
Debt & Liabilities (The "Blood Pressure"): - Total Liabilities: £797,963 (up from £467,391). This is a rapid increase in blood pressure. While it may be funding growth, it needs to be managed carefully. - Long-term Debt (Bank Loans): £2,500 (down from £12,500). This is excellent news. The company is systematically paying down its long-term bank debt, reducing financial risk. - Director Loan: £165,922 owed from a director. This is a significant internal debt. While it shows confidence, it represents a concentration of credit risk.
2. Diagnosis: The Patient is in Recovery and Good Health, but with a Developing Condition
Primary Diagnosis: Successful Turnaround from Critical Condition to Healthy Vitality.
The company was in a critical financial state from 2016 to 2021, with negative shareholders' funds (liabilities exceeding assets). Since then, it has staged a remarkable recovery. The 2025 accounts show a company with strong cash reserves, a robust net worth, and a healthy level of working capital. The patient is no longer in the intensive care unit.
Secondary Diagnosis: Acute Growth Syndrome with Symptoms of Overtrading.
The rapid increase in assets and liabilities suggests the company is in a high-growth phase. The primary symptom is a sharp increase in Other Debtors (£676,334) and Other Creditors (£412,014). These figures are unusually large and not clearly defined by industry standards (SIC 82990 - Other business support services). This lack of clarity is a diagnostic red flag. It suggests the company may be a hub for inter-group transactions or has an unusual business model that requires careful scrutiny. The significant director loan also falls into this category of "opaque" assets.
Secondary Diagnosis: High Dependency on Key Relationships.
The company is reliant on a single director for a significant loan. If this director were to call in the loan, it could create a sudden liquidity crisis. Furthermore, the company's success is heavily tied to the performance of its parent group, as seen in the amounts owed to and from group undertakings.
3. Recommendations: The Prescription for Long-Term Health
- Improve Financial Transparency: The largest items on the balance sheet are "Other Debtors" and "Other Creditors." The company should provide a detailed breakdown of these in future accounts to reassure stakeholders. This is like a doctor asking for a more detailed scan.
- Manage the Director Loan: Formalize the repayment terms for the director's loan of £165,922. While it's a current asset, it is not as liquid as cash. Establishing a clear repayment schedule would strengthen the balance sheet.
- Diversify Funding Sources: To reduce reliance on the director, the company should explore other forms of financing, such as a formal business overdraft or a revolving credit facility, to fund its growth.
- Monitor Cash Conversion Cycle: Given the rapid growth in debtors (money owed to the company), the business must ensure it is collecting payments efficiently. A focus on debtor days (how long it takes to get paid) will be critical to prevent the rapid growth from turning into a cash flow crisis.